Company Overview and News

 
Future Retail to open 20 Big Bazaar stores in FY19, increase reach of small-format stores

2018-09-04 moneycontrol
Future Retail, the retail arm of Kishore Biyani-led Future Group, plans to increase the penetration of small-format stores, said CP Toshniwal, Executive Director, Future Lifestyle Fashions and Chief Financial Officer of the company.
536507 570002 FRLDVR FRL 523574 FLFL

 
Future Retail (₹574.4)

2018-09-03 premium.thehindubusinessline
The outlook for the stock of Future Retail is bullish. The stock surged 3.3 per cent on Monday, breaching decisively the key resistance level of ₹560. The stock has been broadly range-bound between ₹450 and ₹650 over the last several months. Within this range it made a low of ₹453 in mid-August and has reversed sharply higher from there thereby keeping the sideways move intact.
570002 FRLDVR FRL 523574

10
Paytm Mall to host BigBasket in fight with Flipkart, Amazon

2018-08-30 livemint
New Delhi: Paytm Mall, the e-commerce venture backed by China’s Alibaba Group Holding Ltd, is looking to deepen ties with regional retailers as well as partner with online grocery startup BigBasket to compete with Walmart Inc.-controlled Flipkart and Amazon.com Inc.’s local unit, a company executive said.
BABA 570002 FRLDVR FRL 0700 523574 SFTBF 9984 SFTBY

3
Paytm Mall looks to deepen partnerships in fight with Flipkart, Amazon

2018-08-30 moneycontrol
Paytm Mall, the e-commerce venture backed by China's Alibaba Group, is looking to deepen ties with regional retailers as well as partner with top online grocer BigBasket to compete with Walmart-controlled Flipkart and Amazon's local unit, a company executive said.
BRK.A 570002 FRLDVR FRL 523574

 
India's Paytm Mall looks to deepen partnerships in fight with Flipkart, Amazon

2018-08-30 theedgemarkets
NEW DELHI (Aug 30): Paytm Mall, the e-commerce venture backed by China's Alibaba Group, is looking to deepen ties with regional retailers as well as partner with top online grocer BigBasket to compete with Walmart-controlled Flipkart and Amazon's local unit, a company executive said.
570002 FRLDVR FRL 523574

 
India's Paytm Mall looks to deepen partnerships in fight with Flipkart, Amazon

2018-08-29 channelnewsasia
Paytm Mall, the e-commerce venture backed by China's Alibaba Group , is looking to deepen ties with regional retailers as well as partner with top online grocer BigBasket to compete with Walmart-controlled Flipkart and Amazon's local unit, a company executive said.
570002 FRLDVR FRL 523574

 
Steady flow of positive news drives analysts to re-rate retail stocks

2018-08-29 thehindubusinessline
Priya Kansara The shares of retail stocks Aditya Birla Fashion, Shoppers Stop, Future Consumer and Future Retail have gained 7-17 per cent in the last one week — higher than the 1.2 per cent and 1.4 per cent rise seen in Nifty 50 and Nifty 500, respectively — following a string of positive news, such as improved outlook for Aditya Birla Fashion’s businesses and interest of foreign retail giants in Indian e-commerce and retail companies.
523405 570002 500228 FRLDVR FRL 532638 523574 JSWSTEEL JMFINANCIL SHOPERSTOP

 
Future Retail Limited - Shareholders meeting

2018-08-29 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
570002 FRLDVR FRL 523574

 
“We will be among the top 10 in five years” – Munish Sharda, MD and CEO, Future Generali India Life Insurance Company

2018-08-28 freepressjournal.in
Munish Sharda joined Future Generali India Life Insurance Company (FGI-LI) as its Managing Director & CEO in January 2014. That was a challenging time for both the life insurance industry and FGI-LI. In four years, both have made tremendous progress; FGI-LI is now looking to achieve chart-busting numbers on all fronts. Munish, in an interview with The Free Press Journal’s S. Narayanan and RN Bhaskar, talks about how FGI-LI negotiated the tough times and how he sees the way ahead.
570002 FRLDVR FRL 523574

 
Buyback offer of Kaveri Seed opens

2018-08-27 thehindubusinessline
The ₹200-crore buyback offer of Kaveri Seed Company opened on Monday and will end on September 7. The company has offered to buy back up to 29.63 lakh shares, or 4.48 per cent of the total paid-up equity, at ₹675 a share. Kaveri Seed had set August 3 as the record date for shareholders to participate in the buyback, which is through tender route on a proportionate basis. On Monday, just 1,028 shares (0.
570002 LICHSGFIN KSCL FRLDVR FRL 523574 LHFLY 532899 500253

1
IL&FS Investment: Eyes on Q1 results

2018-08-27 thehindubusinessline
Shares of IL&FS Investment Managers will remain in focus, as the company will declare its first-quarter results of FY18. The company, a subsidiary of Infrastructure Leasing & Financial Services Limited (IL&FS), had reported a loss of ₹7.45 crore for the qurter ended March 2018 on revenues of ₹9.28 crore. For FY2018, net profit declined 83.44 per cent to ₹3.97 crore, against ₹23.97 crore reported during the previous fiscal.
570002 LICHSGFIN FSIC FRLDVR FRL 523574 LHFLY 500253

 
Panacea inks deal with Natco, Breckenridge

2018-08-27 thehindubusinessline
Panacea Biotec on Monday inked a tripartite pact with Natco Pharma and Breckenridge Pharmaceutical Inc to manufacture and supply Azacitidine injection, a chemotherapy drug, for the US market. Under its terms, Natco has provided the technology for manufacturing Azacitidine to Panacea Biotec’s Baddi facility. Panacea will manufacture and supply the product, which will be marketed and distributed by Breckenridge in the US.
PANACEABIO 570002 NATCOPHARM LICHSGFIN FRLDVR FRL 524816 523574 LHFLY 531349 500253

 
Company news: HIL Ltd

2018-08-27 thehindubusinessline
HIL Ltd, through its wholly owned subsidiary, HIL International GmbH, Germany, has completed the acquisition of Parador Holdings GmbH after receiving all the regulatory approvals, including anti-trust approvals, from the German Federal Republic. Post this acquisition, HIL will emerge even stronger within its field globally, delivering sustainable value to its stakeholders. The enterprise value of Parador Holdings, a vertically integrated supplier of premium quality flooring solutions, is €82.
570002 LICHSGFIN FRLDVR FRL 523574 LHFLY 500253

 
An evening walk down Dalal Street | Global cues, banks and metals fuel rally on D-Street; Nifty ends just below 11,700

2018-08-27 moneycontrol
What a cracker of a Monday that was for the market! Bulls had it their way throughout the session, gaining with every passing hour. Benchmarks ended the day at record high levels. The Nifty managed to clock 11,700-mark as well.
500325 SUNDARMFIN 570002 RELIANCE FRL 532978 BHRQY SRTRANSFIN 511218 532454 BAJAJFINSV LICHSGFIN FRLDVR RIGD SRRQY 523574 LHFLY BHARTIARTL 590071 500253 RLNIY SNDMY

 
Amaravati Bonds listed on Bombay Stock Exchange

2018-08-27 thehindubusinessline
Andhra Pradesh Chief Minister N. Chandrababu Naidu has said the over-subscription of Amaravati Bonds 2018 reflects the trust of people and investors in the Andhra Pradesh government.
570002 LICHSGFIN FRLDVR FRL 523574 LHFLY 500253

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...